No products in the cart.
Pre-made Vanucizumab benchmark antibody ( Bispecific mAb, anti-ANGPT2;VEGFA therapeutic antibody, Anti-AGPT2/ANG2/LMPHM10;VPF/VEGF/MVCD1 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-612
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Vanucizumab biosimilar, Bispecific mAb, Anti-ANGPT2;VEGFA Antibody: Anti-AGPT2/ANG2/LMPHM10;VPF/VEGF/MVCD1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Vanucizumab (INN; development code RG7221) is an experimental humanized monoclonal antibody designed for the treatment of cancer.
| Products Name (INN Index) | Pre-Made Vanucizumab biosimilar, Bispecific mAb, Anti-ANGPT2;VEGFA Antibody: Anti-AGPT2/ANG2/LMPHM10;VPF/VEGF/MVCD1 therapeutic antibody |
|---|---|
| INN Name | Vanucizumab |
| Target | ANGPT2,VEGFA |
| Format | Bispecific mAb |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Lambda,Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | 4imk:AD:BC/4iml:HL:AB;1bj1:HL:KJ |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;6bft:AB:HL/1cz8:HL:YX |
| Year Proposed | 2014 |
| Year Recommended | 2015 |
| Companies | Roche |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Solid tumours,Colorectal cancer |
| Development Tech | CrossMab |
| Previous Name | NA |
| Gm Offical Target Name | ANGPT2,VEGFA |
| Package |
Previous slide
Next slide
